Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming

DOI IR HANDLE PDF Web Site 14 Citations 28 References Open Access

Search this article

Abstract

<jats:title>Abstract</jats:title><jats:p>Direct cardiac reprogramming from fibroblasts can be a promising approach for disease modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However, postnatal and adult fibroblasts are less efficient for reprogramming compared with embryonic fibroblasts, and barriers to cardiac reprogramming associated with aging remain undetermined. In this study, we screened 8400 chemical compounds and found that diclofenac sodium (diclofenac), a non-steroidal anti-inflammatory drug, greatly enhanced cardiac reprogramming in combination with <jats:italic>Gata4</jats:italic>, <jats:italic>Mef2c</jats:italic>, and <jats:italic>Tbx5</jats:italic> (GMT) or GMT plus <jats:italic>Hand2</jats:italic>. Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip fibroblasts (TTFs), but not in mouse embryonic fibroblasts (MEFs). Mechanistically, diclofenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by silencing inflammatory and fibroblast programs, which were activated in postnatal and adult TTFs. Thus, anti-inflammation represents a new target for cardiac reprogramming associated with aging.</jats:p>

Journal

Citations (14)*help

See more

References(28)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top